Is EFTRW or GBDC a better dividend investment in 2026?

EFTRW currently yields 333333.33% with a 5% 5-year dividend growth rate. GBDC yields 11.85% with 5% growth. The better choice depends on your goal: EFTRW offers higher current income.

What is the dividend yield difference between EFTRW and GBDC?

EFTRW has a forward dividend yield of 333333.33% ($2.00/share annually). GBDC yields 11.85% ($1.50/share annually). The yield gap is 333321.48 percentage points.

Home › Compare › EFTRW vs GBDC

EFTRW vs GBDC: Dividend Comparison 2026

EFTRW yields 333333.33% · GBDC yields 11.85%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EFTRW wins by $8.099219044190773e+31M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EFTRW

● Live price

333333.33%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.099219044190773e+31M

Annual income

$80,944,421,463,343,720,000,000,000,000,000,000,000.00

Full EFTRW calculator →

GBDC

● Live price

11.85%

Share price

$12.66

Annual div

$1.50

5Y div CAGR

51.1%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.78M

Annual income

$16,389,263.41

Full GBDC calculator →

Portfolio growth — EFTRW vs GBDC

📍 EFTRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EFTRW	GBDC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EFTRW + GBDC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EFTRW pays

GBDC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTRW

Annual income on $10K today (after 15% tax)

$28,333,333.33/yr

After 10yr DRIP, annual income (after tax)

$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr

GBDC

Annual income on $10K today (after 15% tax)

$1,007.11/yr

After 10yr DRIP, annual income (after tax)

$13,930,873.90/yr

At 15% tax rate, EFTRW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTRW + GBDC for your $10,000?

EFTRW: 50%GBDC: 50%

100% GBDC50/50100% EFTRW

Portfolio after 10yr

$4.0496095220953863e+31M

Annual income

$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr

Blended yield

99.94%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

EFTRW

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-13.6

Piotroski

2/9

GBDC

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$14.00

+10.6% upside vs current

Range: $13.00 — $15.00

Altman Z

0.6

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTRW buys

GBDC buys

No recent congressional trades found for EFTRW or GBDC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEFTRWGBDC

Forward yield	333333.33% ✓	11.85%
Annual dividend / share	$2.00 ✓	$1.50
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	51.1% ✓
Portfolio after 10y	$8.099219044190773e+31M	$20.78M ✓
Annual income after 10y	$80,944,421,463,343,720,000,000,000,000,000,000,000.00 ✓	$16,389,263.41
Total dividends collected	$8.098906375781879e+31M	$20.36M ✓
Payment frequency	quarterly	quarterly
Sector	Stock	BDC
Analyst consensus	Buy	Buy

Year-by-year: EFTRW vs GBDC ($10,000, DRIP)

Year	EFTRW Portfolio	EFTRW Income/yr	GBDC Portfolio	GBDC Income/yr	Gap
1← crossover	$33,344,033	$33,333,333.33	$12,490	$1,790.28	+$33.33M → EFTRW
2	$103,911,171,366	$103,875,493,250.26	$16,522	$3,157.73	+$103911.15M → EFTRW
3	$302,644,656,190,810	$302,533,471,237,448.00	$23,578	$5,898.68	+$302644656.17M → EFTRW
4	$823,817,797,451,856,400	$823,493,967,669,732,100.00	$37,115	$11,886.75	+$823817797451.82M → EFTRW
5	$2,095,836,995,961,804,000,000	$2,094,955,510,918,530,000,000.00	$66,136	$26,423.57	+$2095836995961804.00M → EFTRW
6	$4,983,251,920,823,462,000,000,000	$4,981,009,375,237,783,000,000,000.00	$137,257	$66,491.44	+$4983251920823461888.00M → EFTRW
7	$11,073,835,968,753,321,000,000,000,000	$11,068,503,889,198,040,000,000,000,000.00	$341,734	$194,868.54	+$1.1073835968753322e+22M → EFTRW
8	$22,999,277,308,531,336,000,000,000,000,000	$22,987,428,304,044,770,000,000,000,000,000.00	$1,050,788	$685,133.02	+$2.2999277308531335e+25M → EFTRW
9	$44,643,905,199,991,210,000,000,000,000,000,000	$44,619,295,973,271,085,000,000,000,000,000,000.00	$4,099,314	$2,974,971.01	+$4.464390519999121e+28M → EFTRW
10	$80,992,190,441,907,720,000,000,000,000,000,000,000	$80,944,421,463,343,720,000,000,000,000,000,000,000.00	$20,775,530	$16,389,263.41	+$8.099219044190773e+31M → EFTRW

EFTRW vs GBDC: Complete Analysis 2026

EFTRW — Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Full EFTRW Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →

📬

Get this EFTRW vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTRW vs SCHD EFTRW vs JEPI EFTRW vs O EFTRW vs KO EFTRW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.